In some patients immune defenses initially rally to attack the cancer, but then are stymied by a molecular brake that shuts down the response. A promising experimental immunotherapy works best in such patients, claims a new study led by researchers at Dana-Farber Cancer Institute and the Yale University School of Medicine.
The antibody drug, known as MPDL3280A, inhibits the brake protein, PD-L1, reviving the response by immune killer T cells, which target and destroy the cancer cells. In recent clinical trials, the PD-L1 checkpoint blocker caused impressive shrinkage of kidney, melanoma, and lung tumors. But, as with other immunotherapy drugs, many patients saw no benefit.
Quiz on Eye Cancer
The eye is composed of several different types of tissues. Thus, cancer of the eye can be of a number of types. See how much you know about eye cancer by taking this quiz.
Advertisement
Researchers report in the November 27 edition of Nature that the antibody was most effective when the patients' immune cells surrounding tumors expressed PD-L1 - a sign that a pre-existing immune response had been shut down by PD-L1. There was less tumor shrinkage in patients who never developed an immune response to the cancer - and, as a result, had less PD-L1 in the cancer and surrounding tissues.
"I think this is a launching point to use these findings as a predictive biomarker," said F. Stephen Hodi, MD, of Dana-Farber, senior author of the report. Hodi directs the Center for Immuno-Oncology and the Melanoma Treatment Center at Dana-Farber. First author is Roy Herbst, MD, PhD, chief of Medical Oncology at the Yale Comprehensive Cancer Center.
![Breast Cancer Screening using Mammogram]( "Breast Cancer Screening using Mammogram")
Breast cancer if detected early can be completely cured. Mammography is used to screen women for breast cancer.
The scientists studied tumor tissue samples from 175 patients treated in clinical trials with MPDL3280A for advanced non-small cell lung cancer, melanoma, kidney cancer, and other cancers. On average, 18 percent of the patients had complete or partial shrinkage of their tumors, with higher or lower rates in different cancer types. Overall, the treatment was well-tolerated, with few severe side-effects, the report said.
An antibody stain that marked the presence of PD-L1 was applied to tumor samples that had been removed from patients prior to treatment. The stain revealed PD-L1 not only in the cancer cells, but also tumor-infiltrating immune cells (ICs). These are T cells and other cells of the immune response that had invaded the tumor in an attempt to destroy them.
The study found greater responses to the antibody drug in patients whose tumor cells and ICs were high in PD-L1. The scientists also looked at PD-L1 expression in samples taken from tumors while the patients were in treatment. They found that tumors that had shrunk as cells died showed increases in PD-L1 in the cancer and infiltrating immune cells.
From these findings, the researchers concluded that for the MPDL3280A antibody to be effective, the patient must have mounted an immune response that was beaten back by PD-L1. This creates a target for the PD-L1-blocking antibody, which removes the brakes on the response and allows the immune cells to attack the tumor.
The scientists called for further studies to define predictors of the response to PD-L1 blockers. "Understanding the profile of non-responders will likely provide even more valuable information," they said, "possibly revealing the diversity of mechanisms controlling anti-tumor immunity."
Breast Cancer Screening using Mammogram
Breast cancer if detected early can be completely cured. Mammography is used to screen women for breast cancer.
Advertisement
The scientists studied tumor tissue samples from 175 patients treated in clinical trials with MPDL3280A for advanced non-small cell lung cancer, melanoma, kidney cancer, and other cancers. On average, 18 percent of the patients had complete or partial shrinkage of their tumors, with higher or lower rates in different cancer types. Overall, the treatment was well-tolerated, with few severe side-effects, the report said.
An antibody stain that marked the presence of PD-L1 was applied to tumor samples that had been removed from patients prior to treatment. The stain revealed PD-L1 not only in the cancer cells, but also tumor-infiltrating immune cells (ICs). These are T cells and other cells of the immune response that had invaded the tumor in an attempt to destroy them.
The study found greater responses to the antibody drug in patients whose tumor cells and ICs were high in PD-L1. The scientists also looked at PD-L1 expression in samples taken from tumors while the patients were in treatment. They found that tumors that had shrunk as cells died showed increases in PD-L1 in the cancer and infiltrating immune cells.
From these findings, the researchers concluded that for the MPDL3280A antibody to be effective, the patient must have mounted an immune response that was beaten back by PD-L1. This creates a target for the PD-L1-blocking antibody, which removes the brakes on the response and allows the immune cells to attack the tumor.
The scientists called for further studies to define predictors of the response to PD-L1 blockers. "Understanding the profile of non-responders will likely provide even more valuable information," they said, "possibly revealing the diversity of mechanisms controlling anti-tumor immunity."
- Scientists analyzed tissue samples from patients who had - and had not - responded to a promising new immunotherapy drug
- They found that patients did best whose cancers had expression of a protein, PD-L1, in immune cells surrounding the tumor cells, to shut down an immune system attack against the cancer
- The study could help identify patients most likely to respond to the new drug, which blocks PD-L1
Interesting Facts About Breast Cancer
Did you know that breast cancer is the most common type of cancer for women? Here are some facts about Breast cancer
Advertisement
 Liver Cancer - AnimationLiver is the largest organ inside the human body. It performs 500 different functions and processes 720 liters of blood per day. The important functions of the liver, the development of liver cancer and it's symptoms are presented in this interactive. | Advertisement
|
Advertisement
Latest Research News
A group of scientists were awarded £1.3 million to create a new “point of care testing” kit that detects Alzheimer's disease biomarkers.
Is there a connection between Osteoporosis and dementia? Yes, loss in bone density may be linked to an increased risk of dementia in older age.
Link between chromosome length and biological aging marker discovered. The finding helps explain why people with longer telomeres have a lower dementia risk.
Integrated structural biology helps discover how the cystic fibrosis transmembrane conductance regulator (CFTR) works.
Link between advanced paternal age and higher risks for reproductive and offspring medical problems has been discovered.